Compare EYE & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EYE | DFTX |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2017 | N/A |
| Metric | EYE | DFTX |
|---|---|---|
| Price | $18.81 | $42.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $31.22 | ★ $38.50 |
| AVG Volume (30 Days) | 2.3M | ★ 3.9M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 202.78 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $1,987,488,000.00 | N/A |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | $47.47 | ★ N/A |
| Revenue Growth | ★ 9.00 | N/A |
| 52 Week Low | $14.75 | $14.62 |
| 52 Week High | $30.02 | $47.01 |
| Indicator | EYE | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 81.21 |
| Support Level | $14.84 | $17.51 |
| Resistance Level | $19.18 | N/A |
| Average True Range (ATR) | 0.95 | 2.55 |
| MACD | 0.36 | 2.19 |
| Stochastic Oscillator | 87.86 | 83.85 |
National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).